CELLCEPT
As listed in the register: CELLCEPT
250 mg · capsule
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Mycophenolate Mofetil
- Made by
- Hoffmann-La Roche Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Mycophenolate mofetil). It describes the substance, not this exact product.
Mycophenolate mofetil (MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite.
MPA is a selective uncompetitive inhibitor of the two isoforms (type I and type II) of inosine monophosphate dehydrogenase (IMPDH) leading to inhibition of the de novo pathway of guanosine nucleotide synthesis and blocks DNA synthesis.
MPA is metabolized principally by glucuronyl transferase to form MPAG, which is not pharmacologically active.
Negligible amount of drug is excreted as MPA (less than 1% of dose) in the urine.
Effect of Food Food (27 g fat, 650 calories) had no effect on the extent of absorption (MPA AUC) of MMF when administered at doses of 1.5 g twice daily to kidney transplant patients.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-09-09
Safety of the active substance
From the US prescribing label for the same active substance (Mycophenolate mofetil). It describes the substance, not this exact product.
WARNING: EMBRYOFETAL TOXICITY, MALIGNANCIES and SERIOUS INFECTIONS Use during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations.
- Mycophenolate Mofetil is contraindicated in patients with a history of hypersensitivity, including anaphylaxis, to mycophenolate mofetil (MMF), mycophenolic acid (MPA) or any component of the drug product [see Warnings and Precautions (5.8)].
- History of hypersensitivity, including anaphylaxis, to mycophenolate mofetil, mycophenolic acid or any component of the drug product ( 4 )
The most common opportunistic infections in patients receiving mycophenolate mofetil with other immunosuppressants were mucocutaneous candida, CMV viremia/syndrome, and herpes simplex.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States18 matching products
European UnionNo exact match for this strength and form
Spain9 matching products
- CELLCEPT 250 mg · cápsula dura2 makers
- MYFENAX 250 mg · cápsula dura2 makers
- MICOFENOLATO DE MOFETILO ACCORD 250 mg · cápsula dura
- MICOFENOLATO DE MOFETILO ARISTO 250 MG · cápsula dura
- MICOFENOLATO DE MOFETILO SANDOZ 250 mg · cápsula dura
- MICOFENOLATO DE MOFETILO TILLOMED 250 mg · cápsula dura
- MICOFENOLATO MOFETILO TEVA 250 mg · cápsula dura
Netherlands6 matching products
- CellCept capsules 250 mg · capsule, hard
- Myclausen 250 mg 250 mg · capsule, hard
- Mycofenolaat Mofetil Accord 250 mg capsules 250 mg · capsule, hard
- Mycofenolaat mofetil Sandoz 250 mg 250 mg · capsule, hard
- Mycofenolaatmofetil Aurobindo 250 mg 250 mg · capsule, hard
- Myfenax 250 mg capsules 250 mg · capsule, hard
SwitzerlandNo exact match for this strength and form
Details
| Made by | Hoffmann-La Roche Limited |
|---|---|
| Active substance | Mycophenolate Mofetil |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 250 mg |
| Form | capsule |
| Classification | L04AA06 · Cancer treatments and immune-system medicines |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02192748 |
| DPD drug code | 19525 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
3 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.